v3.26.1
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Summary of Segment Reconciliation All financial information required for segment reporting that is provided to the chief operating decision-maker is contained within the financial statements and notes to financial statements, with the exception of the disaggregated amounts contained in the table below:

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

(in thousands)

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Research and development:

 

 

 

 

 

 

 

 

 

 

 

 

Salaries and staff costs

 

$

1,847

 

 

$

2,134

 

 

$

3,591

 

 

$

4,103

 

Stock-based compensation

 

 

470

 

 

 

672

 

 

 

788

 

 

 

1,187

 

Clinical trials, outside services, and lab supplies

 

 

3,162

 

 

 

8,306

 

 

 

7,422

 

 

 

15,803

 

Facilities and other

 

 

436

 

 

 

468

 

 

 

879

 

 

 

964

 

Total research and development

 

$

5,915

 

 

$

11,580

 

 

$

12,680

 

 

$

22,057

 

Selling, general and administrative:

 

 

 

 

 

 

 

 

 

 

 

 

Salaries and staff costs

 

$

915

 

 

$

849

 

 

$

3,844

 

 

$

1,775

 

Stock-based compensation

 

 

450

 

 

 

1,011

 

 

 

1,792

 

 

 

1,861

 

Outside services and professional fees

 

 

2,009

 

 

 

1,062

 

 

 

3,438

 

 

 

2,860

 

Facilities and other

 

 

430

 

 

 

396

 

 

 

856

 

 

 

836

 

Total selling, general and administrative

 

$

3,804

 

 

$

3,318

 

 

$

9,930

 

 

$

7,332

 

Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:

 

 

 

June 30,

 

 

 

2026

 

 

2025

 

Options to purchase Common Stock

 

 

11,788,535

 

 

 

11,701,432

 

Warrants to purchase Common Stock

 

 

432

 

 

 

2,787,714

 

Series A Convertible Preferred Stock

 

 

877

 

 

 

877

 

 

 

11,789,844

 

 

 

14,490,023